Bris­tol My­ers cell ther­a­py man­u­fac­tur­ing site gets thumbs-up from FDA

A new Bris­tol My­ers Squibb cell man­u­fac­tur­ing site that is ex­pect­ed to make the CAR-T ther­a­py Breyanzi has re­ceived FDA ap­proval to start pro­duc­tion.

The phar­ma an­nounced that its 244,000-square-foot cell ther­a­py man­u­fac­tur­ing site in De­vens, MA, has got­ten a OK from the FDA to be­gin com­mer­cial pro­duc­tion. The man­u­fac­tur­ing fa­cil­i­ty is the lat­est ex­pan­sion at the BMS cam­pus there, which al­ready has de­vel­op­ing, test­ing and man­u­fac­tur­ing ca­pa­bil­i­ties for BMS med­i­cines. The fa­cil­i­ty has brought in 500 new em­ploy­ees as well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER